Terms: = Kidney tumors AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Prognosis
835 results:
1. Overexpression of cyclin F/CCNF as an independent prognostic factor for poor survival in clear cell renal cell carcinoma.
Kwiatkowski M; Krajewski A; Durślewicz J; Buchholz K; Grzanka D; Gagat M; Zabrzyński J; Klimaszewska-Wiśniewska A
Sci Rep; 2024 Apr; 14(1):9280. PubMed ID: 38654021
[TBL] [Abstract] [Full Text] [Related]
2. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract] [Full Text] [Related]
3. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract] [Full Text] [Related]
4. PMab-314: An Anti-Giant Panda Podoplanin Monoclonal Antibody.
Ouchida T; Li G; Suzuki H; Yanaka M; Nakamura T; Handa S; Tanaka T; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):53-58. PubMed ID: 38593441
[TBL] [Abstract] [Full Text] [Related]
5. Molecular characteristics and prognostic significances of lysosomal-dependent cell death in kidney renal clear cell carcinoma.
He S; Sun J; Guan H; Su J; Chen X; Hong Z; Wang J
Aging (Albany NY); 2024 Mar; 16(5):4862-4888. PubMed ID: 38460947
[TBL] [Abstract] [Full Text] [Related]
6. Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer.
Mizutani K; Sugiyama S; Kameyama K; Kamei S; Yokoi S; Morikawa A; Takeuchi M; Seike K; Yamada T; Ehara H; Sawada S; Hirade K; Furuta H; Matsunaga K; Yamada T; Sakamoto I; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2024; 21(2):203-212. PubMed ID: 38423595
[TBL] [Abstract] [Full Text] [Related]
7. EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway.
Zhou X; Dong S; Zhou Y; He Z; Zhang Z; Liao L; Zou B; Zheng X; Peng K; Duan X
Mol Carcinog; 2024 May; 63(5):951-961. PubMed ID: 38362840
[TBL] [Abstract] [Full Text] [Related]
8. Pan-cancer analysis of RNA 5-methylcytosine reader (ALYREF).
Ye X; Tuo Z; Chen K; Wu R; Wang J; Yu Q; Ye L; Miyamoto A; Yoo KH; Zhang C; Wei W; Li D; Feng D
Oncol Res; 2024; 32(3):503-515. PubMed ID: 38361753
[TBL] [Abstract] [Full Text] [Related]
9. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
[TBL] [Abstract] [Full Text] [Related]
10. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
[TBL] [Abstract] [Full Text] [Related]
11. Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers.
Wang B; Jiang J; Luo D; Wang X
Sci Rep; 2024 Feb; 14(1):3476. PubMed ID: 38342956
[TBL] [Abstract] [Full Text] [Related]
12. Correlations of SDF-1ɑ and XRCC1 gene polymorphisms with the risk of renal cancer development and bioinformatics studies of SDF-1α and XRCC1 and the prognosis of renal cancer.
Zhang W; Su Y; Yue G; Zhao L; Li H; Jia M; Wang Y; Liu D; Wang H; Gao Y
Sci Rep; 2024 Feb; 14(1):3367. PubMed ID: 38337001
[TBL] [Abstract] [Full Text] [Related]
13. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma.
Li X; Deng X; Liu T; Zhang W; Tao J
Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964
[TBL] [Abstract] [Full Text] [Related]
14. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
15. Hsa_circ_0086414/transducer of ERBB2 (TOB2) axis-driven lipid elimination and tumor suppression in clear cell renal cell cancer via perilipin 3.
Meng X; Li W; Yu T; Lu F; Wang C; Yuan H; Yang W; Dong W; Xiao W; Zhang X
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129636. PubMed ID: 38272402
[TBL] [Abstract] [Full Text] [Related]
16. NKG2A
Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
[TBL] [Abstract] [Full Text] [Related]
17. Urological Cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients.
Ozgor F; Caglar U; Halis A; Cakir H; Aksu UC; Ayranci A; Sarilar O
Clin Genitourin Cancer; 2024 Apr; 22(2):454-457.e4. PubMed ID: 38246831
[TBL] [Abstract] [Full Text] [Related]
18. A pan-cancer analysis of the prognostic implication and oncogenic role of tubulin epsilon and delta complex 2 (TEDC2) in human tumors.
Liu Y; Zhu J; Shen J; Lu Y; Pan K; Tong C; Wang Y
Front Immunol; 2023; 14():1272108. PubMed ID: 38239349
[TBL] [Abstract] [Full Text] [Related]
19. Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma.
Ma F; Wang S; Xu L; Huang W; Shi G; Sun Z; Cai W; Wu Z; Huang Y; Meng J; Sun Y; Fang M; Cheng M; Ji Y; Hu T; Zhang Y; Gu B; Zhang J; Song S; Sun Y; Yan W
Commun Biol; 2024 Jan; 7(1):91. PubMed ID: 38216635
[TBL] [Abstract] [Full Text] [Related]
20. SLFN11 promotes clear cell renal cell carcinoma progression via the PI3K/AKT signaling pathway.
Wang HX; Zhao ZP; Du XY; Peng SL; Xu HY; Tang W; Yang L
Med Oncol; 2024 Jan; 41(2):54. PubMed ID: 38206539
[TBL] [Abstract] [Full Text] [Related]
[Next]
